Law Office of Brodsky & Smith, LLC Announces Investigation of OPNET Technologies, Inc.
02 November 2012 - 11:30PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
OPNET Technologies, Inc. (“OPNET” or the “Company”) (Nasdaq: OPNT)
relating to the proposed acquisition by Riverbed Technology
(“Riverbed”).
Under the terms of the transaction, OPNET shareholders will
receive only $36.55 in cash and a fixed 0.2774 shares of Riverbed
common stock for each share on OPNET common stock they own. The
transaction values OPNET at approximately $42.82 per share. The
investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of OPNET
for not acting in the Company’s shareholders' best interests in
connection with the sale process to Riverbed. The investigation
seeks to determine if the price being paid is fair and if conflicts
of interests played a role in the transaction as OPNET’s CEO and
CTO will remain with the combined company.
If you own shares of OPNET stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/494-opnt-opnet-technologies-inc.html, by
calling toll free 877-LEGAL-90.
Attorney Advertising. Past results do not guarantee a similar
outcome.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Opiant Pharmaceuticals Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Brodsky & Smith, LLC News-Artikel